1. Patients in the ritlecitinib group showed significant improvements in alopecia symptoms, with Severity of Alopecia Tool (SALT) scores ≤ 20, compared to placebo. 2. Adverse events between groups were comparable; there were no reported deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: Alopecia areata is an autoimmune form of hair loss that affects both
NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) said Friday that the U.S. Food and Drug Administration accepted for filing the New Drug Application or NDA for ritlecitinib for adults and adolescents